-+ 0.00%
-+ 0.00%
-+ 0.00%
Roche's Genentech wins first FDA approval for primary membranous nephropathy treatment with Gazyva
Share
Listen to the news
Roche's Genentech wins first FDA approval for primary membranous nephropathy treatment with Gazyva
  • Roche unit Genentech's Gazyva becomes first FDA-approved treatment for adults with primary membranous nephropathy at risk of disease progression.
  • Phase III MAJESTY showed complete proteinuria remission at two years in 36.1% receiving Gazyva versus 5.7% with tacrolimus (p<0.001).
  • The decision marks Gazyva's third FDA approval in immune-mediated kidney diseases, following idiopathic nephrotic syndrome and lupus nephritis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via Business Wire (Ref. ID: 202611160100BIZWIRE_USPR_____20261115_BW934247) on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending